Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
2000 1
2003 1
2005 1
2006 3
2007 2
2008 5
2009 4
2010 6
2011 6
2012 16
2013 5
2014 9
2015 15
2016 20
2017 18
2018 29
2019 28
2020 19
Text availability
Article attribute
Article type
Publication date

Search Results

168 results
Results by year
Filters applied: . Clear all
Page 1
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
McGuire P, Robson P, Cubala WJ, Vasile D, Morrison PD, Barron R, Taylor A, Wright S. McGuire P, et al. Am J Psychiatry. 2018 Mar 1;175(3):225-231. doi: 10.1176/appi.ajp.2017.17030325. Epub 2017 Dec 15. Am J Psychiatry. 2018. PMID: 29241357 Clinical Trial.
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed the safety and effectiveness of CBD in patients with schizophrenia. ...CONCLUSIONS: These findings suggest that CBD has beneficial effe …
OBJECTIVE: Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties. The authors assessed th …
A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia.
Osborne AL, Solowij N, Weston-Green K. Osborne AL, et al. Neurosci Biobehav Rev. 2017 Jan;72:310-324. doi: 10.1016/j.neubiorev.2016.11.012. Epub 2016 Nov 22. Neurosci Biobehav Rev. 2017. PMID: 27884751 Review.
Cannabidiol (CBD), a component of the cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability to improve cognitive impairment has not been thoroughly explored. ...RESULTS: CBD improves cognition in multiple preclinical models of cognit …
Cannabidiol (CBD), a component of the cannabis plant, has anti-inflammatory and antipsychotic-like properties; however, its ability t …
Does cannabidiol have a role in the treatment of schizophrenia?
Gururajan A, Malone DT. Gururajan A, et al. Schizophr Res. 2016 Oct;176(2-3):281-290. doi: 10.1016/j.schres.2016.06.022. Epub 2016 Jul 1. Schizophr Res. 2016. PMID: 27374322 Review.
Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and economic strain on the individual and society-at-large. ...In this regard, cannabidiol (CBD), a non-psychoactive constituent of Cannabis sativa, has shown significant promi …
Schizophrenia is a debilitating psychiatric disorder which places a significant emotional and economic strain on the individual and s …
Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.
Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Crippa JA, et al. Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Front Immunol. 2018. PMID: 30298064 Free PMC article. Review.
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experiment …
Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subj …
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M. Boggs DL, et al. Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932. doi: 10.1007/s00213-018-4885-9. Epub 2018 Apr 5. Psychopharmacology (Berl). 2018. PMID: 29619533 Clinical Trial.
RATIONALE: Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; however, CBD has never been evaluated for the treatment of cognitive impairments associated with schizophrenia (CIAS). ...CONCLUSIONS: A …
RATIONALE: Preliminary evidence suggests that cannabidiol (CBD) may be effective in the treatment of neurodegenerative disorders; how …
Is cannabidiol an effective treatment for schizophrenia?
Guinguis R, Ruiz MI, Rada G. Guinguis R, et al. Medwave. 2017 Aug 9;17(7):e7010. doi: 10.5867/medwave.2017.07.7010. Medwave. 2017. PMID: 28820868 English, Spanish.
Cannabidiol has recently been proposed as an antipsychotic for schizophrenia. However, its clinical use and safety is controversial. ...We concluded cannabidiol probably does not improve symptoms in schizophrenia and leads to frequent side effects....
Cannabidiol has recently been proposed as an antipsychotic for schizophrenia. However, its clinical use and safety is controve …
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia.
Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, Klosterkötter J, Hellmich M, Koethe D. Leweke FM, et al. Transl Psychiatry. 2012 Mar 20;2(3):e94. doi: 10.1038/tp.2012.15. Transl Psychiatry. 2012. PMID: 22832859 Free PMC article. Clinical Trial.
In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsychotic, in acute schizophrenia to evaluate the clinical relevance of our initial findings. ...The results suggest that inhibition of …
In our translational approach, we performed a double-blind, randomized clinical trial of cannabidiol vs amisulpride, a potent antipsy …
Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments.
Renard J, Norris C, Rushlow W, Laviolette SR. Renard J, et al. Neurosci Biobehav Rev. 2017 Apr;75:157-165. doi: 10.1016/j.neubiorev.2017.02.006. Epub 2017 Feb 7. Neurosci Biobehav Rev. 2017. PMID: 28185872 Review.
Growing clinical and pre-clinical evidence points to a critical role for cannabidiol (CBD), the largest phytochemical component of cannabis, as a potential pharmacotherapy for various neuropsychiatric disorders. ...Together with clinical evidence showing that CBD may norma …
Growing clinical and pre-clinical evidence points to a critical role for cannabidiol (CBD), the largest phytochemical component of ca …
A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential.
White CM. White CM. J Clin Pharmacol. 2019 Jul;59(7):923-934. doi: 10.1002/jcph.1387. Epub 2019 Feb 7. J Clin Pharmacol. 2019. PMID: 30730563 Review.
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, ranging from a US Food and Drug Administration (FDA)-approved product called Epidiolex to products created for medical marijuana dispensaries …
Cannabidiol (CBD) is a highly touted product for many different disorders among the lay press. Numerous CBD products are available, r …
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders.
Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, Katz R, Di Marzo V, Jutras-Aswad D, Notcutt WG, Martinez-Orgado J, Robson PJ, Rohrback BG, Thiele E, Whalley B, Friedman D. Devinsky O, et al. Epilepsia. 2014 Jun;55(6):791-802. doi: 10.1111/epi.12631. Epub 2014 May 22. Epilepsia. 2014. PMID: 24854329 Free PMC article. Review.
To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. ...CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxie …
To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy …
168 results
Jump to page
Feedback